12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Deals

Pozen, CPP Investment Board deal

Pozen sold its royalty and milestone rights associated with U.S. sales of migraine drug Treximet sumatriptan/naproxen to CPPIB's CPPIB Credit Investments Inc. unit for $75 million. Pozen is eligible for milestones and royalties from...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >